BYSTOLIC
What it isBeta-1 antagonist with beta-3 agonism and nitric-oxide vasodilation; hypertension.
Why this oneIt uniquely couples beta-1 blockade to beta-3-mediated vasodilation, separating it from conventional beta blockers.
What limits itBradycardia still limits use; beta-1 selectivity fades as exposure rises, and CYP2D6 inhibition can markedly raise levels.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults | 5 mg QD | individualized | 40 mg QD |
Titration Increase at 2-week intervals
Renal Severe (CLcr <30 mL/min): start 2.5 mg QD, titrate slowly; not studied in dialysis
Hepatic Moderate impairment: start 2.5 mg QD, titrate slowly; contraindicated/not recommended in severe (Child-Pugh >B)
Pregnancy Data insufficient; third-trimester beta-blocker risk of neonatal hypotension, bradycardia, hypoglycemia, respiratory depression
Lactation Not recommended during nursing (beta-blocker risk, esp. bradycardia)
NO BOXED WARNINGS
Principal riskBradycardia; the most beta-1 selective
Cost, est. cash$5–$150/month
Generic entry2015
Legacy pregnancy categoryC
Defining liabilityBradycardia, hypotension and bronchospasm; overdose may cause conduction block or cardiogenic shock.

Open Nebivolol in the interactive console ↗

